TBMC will leverage existing resources to integrate intelligent and smart platform to establish various biopharmaceuticals manufacturing facility.

RephImmune is pioneering a new frontier in cancer immunotherapy with its proprietary platform, Reconstitute-Immunity Antigen-Cell Engager (RACE). This cutting-edge technology is rooted in regeneration biology and is specifically designed to reprogram and rebuild the immune system to effectively target and eliminate solid tumors.

At the core of RACE is a sophisticated algorithmic framework developed by RephImmune, which enables the identification, reassembly, and regeneration of immune components. The platform begins with the selection of 150 promising protein candidates and expands into a vast library of over 500,000 synthetically engineered novel proteins. These proteins are carefully designed and verified for their ability to modulate immune responses and engage tumor-specific antigens.

What sets RephImmune apart is its capacity to reconstitute cellular immunity across 13 different types of immune cells, including various subsets of T cells and innate immune cells. Through this process, the company has developed a novel engineered RACE-T cell specifically designed to attack and destroy solid tumors.

Importantly, the RACE platform is AI-compatible, meaning it can be trained and optimized through machine learning models. This integration of computational biology and artificial intelligence allows for continuous improvement and personalization of immunotherapy strategies, making RephImmune’s approach not only innovative but also scalable and adaptive to future clinical challenges.